Wednesday, March 18, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

CDC clarifies vaccine guidelines and mixing

The Centers for Disease Control and Prevention updated its guidance on Thursday on the administration of the two coronavirus vaccines currently approved for Emergency Use Authorization.

The guidance clarifies several questions public health practitioners have recently asked. Can the two doses of the Pfizer and Moderna vaccines be split, and how long do patients have to get the second dose of the vaccine?

Both doses of the vaccine require patients to return for a booster. For the Pfizer vaccine, the second dose is recommended three weeks after the first dose. The second dose of the Moderna vaccine is due four weeks later.

The CDC said that it continues to recommend that the same type of vaccine be administered to patients. But if only the opposite type of vaccine is available, the CDC said that the other vaccine can be administered and is considered effective.

Source: CDC

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!